Fujiwara K, Yamauchi H, Yoshida T, Suzuki S, Oda T, Kohno I
Department of Obstetrics and Gynecology, Kawasaki Medical School, 577 Matsushima, Kurashiki-City, 701-0192, Japan.
Gynecol Oncol. 1998 Aug;70(2):231-5. doi: 10.1006/gyno.1998.5075.
Intraperitoneal chemotherapy for minimal residual ovarian cancer has been shown to be effective. However, evaluation of the response without a second-look laparotomy (SLL) is impossible because such disease is unmeasurable by radiographic studies. In this prospective pilot study, we evaluated the relationship between implantable port system (IPS)-cytology and findings by SLL in patients with unmeasurable diseases.
Patients eligible for this study were those who had either unmeasurable residual disease at the time of initial surgery or measurable residual disease which became unmeasurable before second-look laparotomy. At the time of the initial surgery, the IPS was placed and intraperitoneal chemotherapy was administered. To obtain IPS-cytology, approximately 500 ml of saline was infused, with the patients changing their position to wash the peritoneal surface as thoroughly as possible. More than 20 ml of saline was recovered for cytological evaluation. SLL was performed after 4 to 10 courses of chemotherapy. Results of IPS-cytology obtained immediately before SLL and the SLL findings were compared.
Forty-four patients were entered into this study. Twenty-nine patients had unmeasurable residual disease at the time of initial surgery and 15 had measurable residual disease which became unmeasurable before SLL. Only 40 patients were eligible for evaluation because catheter failure occurred in 4 patients. Three of the 26 patients who had negative IPS-cytology results were found to have positive SLL results. All 14 patients who had positive IPS-cytology results also had positive SLL results.
IPS-cytology can detect intraperitoneal persistent disease in patients with unmeasurable residual ovarian cancer. Persistent positive IPS-cytology can indicate a negative response to chemotherapy, thus making it possible to avoid SLL. Further study with a larger number of patients is required to determine the role of negative IPS-cytology.
已证明腹腔内化疗对微小残留卵巢癌有效。然而,由于此类疾病无法通过影像学检查测量,因此在没有二次剖腹探查(SLL)的情况下评估反应是不可能的。在这项前瞻性试点研究中,我们评估了不可测量疾病患者的可植入端口系统(IPS)细胞学与二次剖腹探查结果之间的关系。
符合本研究条件的患者是那些在初次手术时存在不可测量的残留疾病或在二次剖腹探查前可测量的残留疾病变为不可测量的患者。在初次手术时,放置IPS并进行腹腔内化疗。为了获得IPS细胞学样本,注入约500毫升生理盐水,患者改变体位以尽可能彻底地冲洗腹膜表面。回收超过20毫升的生理盐水用于细胞学评估。在化疗4至10个疗程后进行二次剖腹探查。比较二次剖腹探查前立即获得的IPS细胞学结果和二次剖腹探查结果。
44名患者进入本研究。29名患者在初次手术时存在不可测量的残留疾病,15名患者在二次剖腹探查前可测量的残留疾病变为不可测量。由于4名患者出现导管故障,只有40名患者符合评估条件。26名IPS细胞学结果为阴性的患者中有3名二次剖腹探查结果为阳性。所有14名IPS细胞学结果为阳性的患者二次剖腹探查结果也为阳性。
IPS细胞学可以检测不可测量残留卵巢癌患者的腹腔内持续性疾病。持续性IPS细胞学阳性可能表明对化疗反应不佳,从而有可能避免二次剖腹探查。需要对更多患者进行进一步研究以确定阴性IPS细胞学的作用。